Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001042384 | SCV001206062 | pathogenic | Argininosuccinate lyase deficiency | 2023-10-15 | criteria provided, single submitter | clinical testing | This sequence change replaces methionine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 21 of the ASL protein (p.Met21Thr). This variant is present in population databases (rs774392615, gnomAD 0.004%). This missense change has been observed in individual(s) with hyperammonemia (Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 840407). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ASL protein function. For these reasons, this variant has been classified as Pathogenic. |
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV003230623 | SCV003928898 | uncertain significance | not specified | 2023-04-25 | criteria provided, single submitter | clinical testing | Variant summary: ASL c.62T>C (p.Met21Thr) results in a non-conservative amino acid change located in the Fumarate lyase, N-terminal domain (IPR022761) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 250952 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.62T>C in individuals affected with Argininosuccinic Aciduria and no experimental evidence demonstrating its impact on protein function have been published in the literature. Two ClinVar submitters have assessed the variant since 2014: one classified the variant as uncertain significance and one as pathogenic. Based on the evidence outlined above, the variant was classified as uncertain significance. |
| Natera, |
RCV001042384 | SCV002075988 | uncertain significance | Argininosuccinate lyase deficiency | 2020-01-24 | no assertion criteria provided | clinical testing |